NewAmsterdam Pharma Co N.V.
NAMSW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 9 institutions reported holding it in 13F filings for Q2 2026, worth $28.1M in total; no superinvestor holds it.
Other share classesNAMS
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:24 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $203.8M (905.7% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 20-F/A |
| Reported | Jan 9, 2026 | Feb 26, 2025 | Feb 28, 2024 | – |
| Revenue | $22.5M | $45.6M | $14.1M | – |
| Operating expenses | $248.2M | $221.9M | $197.1M | – |
| Research and development | $141.8M | $151.4M | $159.4M | – |
| Selling, general and administrative | $106.4M | $70.4M | $37.6M | – |
| Operating income | -$225.7M | -$176.3M | -$183.0M | – |
| Income tax | – | -$1.00K | $27.0K | – |
| Net income | -$203.8M | -$241.6M | -$176.9M | – |
| EPS, basic | $-1.72 | $-2.56 | $-2.15 | – |
| EPS, diluted | $-1.72 | $-2.56 | $-2.15 | – |
| Weighted shares, basic | 118.4M | 94.4M | 82.2M | 39.6M |
| Weighted shares, diluted | 118.4M | 94.4M | 82.2M | – |
| Margins and growth | ||||
| Operating margin | -1002.9% | -386.9% | -1298.6% | – |
| Net margin | -905.7% | -530.3% | -1255.8% | – |
| Revenue growth, year over year | −50.6% | +223.4% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 20-F/A |
| Reported | Jan 9, 2026 | Feb 26, 2025 | Feb 28, 2024 | – |
| Cash and equivalents | $490.0M | $771.7M | $340.4M | – |
| Short-term investments | $146.2M | $62.4M | – | – |
| Total current assets | $675.7M | $863.4M | $346.8M | – |
| Property, plant and equipment | $383.0K | $242.0K | $46.0K | – |
| Total assets | $769.3M | $864.6M | $347.1M | – |
| Accounts payable | $8.97M | $4.74M | $16.9M | – |
| Total current liabilities | $85.8M | $106.9M | $49.9M | – |
| Total liabilities | $85.9M | $107.1M | $58.7M | – |
| Shareholders' equity | $683.4M | $757.5M | $288.4M | – |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 20-F/A |
| Reported | Jan 9, 2026 | Feb 26, 2025 | Feb 28, 2024 | – |
| Operating cash flow | -$147.8M | -$158.6M | -$141.2M | – |
| Capital expenditures | $246.0K | $672.0K | $24.0K | – |
| Free cash flow | -$148.0M | -$159.2M | -$141.2M | – |
| Depreciation and amortization | $220.0K | $113.0K | $49.0K | – |
| Stock-based compensation | $59.4M | $33.6M | $24.6M | – |
| Investing cash flow | -$174.9M | -$62.8M | -$24.0K | – |
| Financing cash flow | $29.5M | $659.5M | $8.91M | – |
| Ratio | ||||
| Stock-based compensation, % of revenue | 264.1% | 73.8% | 174.4% | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 2, 2026 | 119.9M | +5.8% | SEC |
| Aug 3, 2026 | 119.5M | +6.1% | SEC |
| Apr 29, 2026 | 116.9M | +4.1% | SEC |
| Feb 5, 2026 | 115.0M | +4.7% | SEC |
| Oct 31, 2025 | 113.4M | +22.7% | SEC |
| Jul 31, 2025 | 112.6M | +25.1% | SEC |
| May 2, 2025 | 112.3M | +24.8% | SEC |
| Feb 18, 2025 | 109.8M | +23.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.